Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yi Ba

Showing results (61-70 of 205) with videos related to

Pageof 21
Sort By:
Molecular Therapy : the Journal of the American Society of Gene Therapy|February 20, 2018
Exosomes Serve as Nanoparticles to Deliver Anti-miR-214 to Reverse Chemoresistance to Cisplatin in Gastric CancerXinyi Wang, Haiyang Zhang, Ming Bai, et al.
Signal Transduction and Targeted Therapy|May 11, 2026
The evolving global landscape of first-in-class oncology drug innovationXiangyun Mao, Zhaoqing Wang, Shu Kong, et al.
Cancer Biology & Medicine|December 26, 2023
Phase Ib study of anti-EGFR antibody (SCT200) in combination with anti-PD-1 antibody (SCT-I10A) for patients with RAS/BRAF wild-type metastatic colorectal cancerMing Bai, Yao Lu, Chunmei Shi, et al.
EMBO Reports|November 15, 2021
lncRNA-encoded pep-AP attenuates the pentose phosphate pathway and sensitizes colorectal cancer cells to OxaliplatinXinyi Wang, Haiyang Zhang, Shengjie Yin, et al.
Cancer|August 17, 2025
Anti-PD-1 antibody (SCT-I10A) plus anti-EGFR antibody (SCT200) in patients with advanced esophageal squamous cell carcinoma: A multicenter, open-label, phase 1b clinical trialMing Bai, Yao Lu, Lin Shen, et al.
Cell Death & Disease|September 10, 2024
A spatiotemporal comparative analysis on tumor immune microenvironment characteristics between neoadjuvant chemotherapy and preoperative immunotherapy for ESCCZhengyang Zhou, Hongdian Zhang, Jian Du, et al.
Cancer Immunology, Immunotherapy : CII|June 4, 2024
Combinational zimberelimab plus lenvatinib and chemotherapy for alpha-fetoprotein elevated, advanced gastric cancer patients (AFPGC): a phase 1 dose-escalation studyTing Deng, Feixue Wang, Le Zhang, et al.
Cellular Physiology and Biochemistry : International Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology|November 29, 2017
MiR-193a-3p is an Important Tumour Suppressor in Lung Cancer and Directly Targets KRASQian Fan, Xiuting Hu, Haiyang Zhang, et al.
Oncotarget|June 16, 2016
Onco-miR-130 promotes cell proliferation and migration by targeting TGFβR2 in gastric cancerJingjing Duan, Haiyang Zhang, Yanjun Qu, et al.
Therapeutic Advances in Medical Oncology|August 2, 2023
Safety, tolerability, and pharmacokinetics of an anti-LAG-3 antibody SHR-1802 in patients with advanced solid tumors: a phase I dose-escalation and dose-expansion studyTing Deng, Zhigang Liu, Zhengquan Han, et al.
Pageof 21

Showing results (61-70 of 205) with videos related to

Sort By:
Pageof 21
Molecular Therapy : the Journal of the American Society of Gene Therapy|February 20, 2018
Exosomes Serve as Nanoparticles to Deliver Anti-miR-214 to Reverse Chemoresistance to Cisplatin in Gastric CancerXinyi Wang, Haiyang Zhang, Ming Bai, et al.
Signal Transduction and Targeted Therapy|May 11, 2026
The evolving global landscape of first-in-class oncology drug innovationXiangyun Mao, Zhaoqing Wang, Shu Kong, et al.
Cancer Biology & Medicine|December 26, 2023
Phase Ib study of anti-EGFR antibody (SCT200) in combination with anti-PD-1 antibody (SCT-I10A) for patients with RAS/BRAF wild-type metastatic colorectal cancerMing Bai, Yao Lu, Chunmei Shi, et al.
EMBO Reports|November 15, 2021
lncRNA-encoded pep-AP attenuates the pentose phosphate pathway and sensitizes colorectal cancer cells to OxaliplatinXinyi Wang, Haiyang Zhang, Shengjie Yin, et al.
Cancer|August 17, 2025
Anti-PD-1 antibody (SCT-I10A) plus anti-EGFR antibody (SCT200) in patients with advanced esophageal squamous cell carcinoma: A multicenter, open-label, phase 1b clinical trialMing Bai, Yao Lu, Lin Shen, et al.
Cell Death & Disease|September 10, 2024
A spatiotemporal comparative analysis on tumor immune microenvironment characteristics between neoadjuvant chemotherapy and preoperative immunotherapy for ESCCZhengyang Zhou, Hongdian Zhang, Jian Du, et al.
Cancer Immunology, Immunotherapy : CII|June 4, 2024
Combinational zimberelimab plus lenvatinib and chemotherapy for alpha-fetoprotein elevated, advanced gastric cancer patients (AFPGC): a phase 1 dose-escalation studyTing Deng, Feixue Wang, Le Zhang, et al.
Cellular Physiology and Biochemistry : International Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology|November 29, 2017
MiR-193a-3p is an Important Tumour Suppressor in Lung Cancer and Directly Targets KRASQian Fan, Xiuting Hu, Haiyang Zhang, et al.
Oncotarget|June 16, 2016
Onco-miR-130 promotes cell proliferation and migration by targeting TGFβR2 in gastric cancerJingjing Duan, Haiyang Zhang, Yanjun Qu, et al.
Therapeutic Advances in Medical Oncology|August 2, 2023
Safety, tolerability, and pharmacokinetics of an anti-LAG-3 antibody SHR-1802 in patients with advanced solid tumors: a phase I dose-escalation and dose-expansion studyTing Deng, Zhigang Liu, Zhengquan Han, et al.
Pageof 21